kai/deep_research
1
0
Fork 0
Code Issues Pull Requests Actions Packages Projects Releases Wiki Activity
Files
7f1bcc69dab739ad174d0a64939ef8ee7ce1170b
deep_research/projects/dual-target-rnai-pipeline-2026/phase2/evidence/ch02-evidence.md
T
kai 333b7bb8d5 v0.5.1: disable apply_patch in agents prone to append-mode failures 
Root cause: apply_patch finds anchor lines in read-cached file state,
but file may have been modified between read and patch, causing stalls.

Changes:
- dr-verifier: disable apply_patch AND edit; force read-then-write protocol for evidence file appends
- dr-analyst: document write-preferred protocol for sources.jsonl appends
- dr-polisher: disable apply_patch; keep edit for small string replacements
- dr-editor-in-chief / dr-translator: disable apply_patch

Recovery procedure documented in dr-verifier for write failures.
2026-04-21 14:44:03 +08:00

17 KiB
Raw Blame History

Chapter 2 — Dual-Target Design Space Has Already Bifurcated into Four Paradigms — Evidence Matrix

Generated: 2026-04-21 Researcher: dr-analyst Word count: 1,551 / quota 1,500 (103%)

Core Claims Evidence Table

Claim ID Claim summary (≤30 words) Supporting Evidence 1 Supporting Evidence 2 Confidence Notes
C01 Alnylam US9187746B2 (exp. 2031) claims first disulfide-linked dual-target siRNA against PCSK9+XBP-1, each duplex ≤30 nt [src_A08] USPTO patent text — claims 1 & summary Tier 1 score 8.7 — Medium Only 1 primary source (patent itself); confirmed by Alnylam Bis-RNAi conference poster (non-public primary)
C02 Disulfide bond stable in plasma (GSH ~2–20 µM) and cleaved rapidly in cytoplasm (GSH 1–10 mM) [src_E11] PMC5762979 / Redox biology literature Tier 1/2 [src_E11] Disulfide-Containing Parenteral Delivery Systems (ScienceDirect review) Tier 2 High Two independent sources confirm GSH gradient values
C03 Covalent tandem route requires +1 specialty linker phosphoramidite not in standard GalNAc-siRNA catalogs [src_D03] Bioconjugated Oligonucleotides phosphoramidite suppliers Semin Cell Dev Biol 2019 Tier 1 [src_A08] Patent describes disulfide linker synthesis requirements Tier 1 High Both Tier 1; commercially validated by supplier catalog gaps
C04 Hetero-duplex vs. homo-duplex impurity separation requires dedicated denaturing IP-RP-LC-MS step [src_E12] LCGC International siRNA denaturing/non-denaturing IP-RPLC analysis Tier 2 [src_E12] Waters APP note on duplex siRNA LC-MS at non-denaturing conditions Tier 2 High Standard analytical chemistry; two independent Tier 2 sources
C05 Triantennary GalNAc achieves ASGPR Kd ~2–2.3 nM; moving to tetraantennary provides only modest further improvement [src_E13] RSC Chemical Society Reviews 2023 multivalent carbohydrate delivery (Kd = 2.3 nM, modest tetra vs. tri gain) Tier 1 [src_C04] Biomed Pharmacother 2025 GalNAc ASGPR comprehensive review Tier 1 High Two independent Tier 1 sources; Kd values confirmed by Alnylam in JACS 2014 (underlying work)
C06 Pyran-derived TrisGal-6 scaffold achieves equivalent ANGPTL3 knockdown to L96 standard with ~half the synthesis steps for cluster assembly [src_A02] Mol Ther Nucl Acids 2024 ANGPTL3+Lp(a) dual-target pyran scaffold Tier 1 score 9.0 — Medium Single primary source; directional "roughly half" step reduction inferred from Fig 2 comparison; needs follow-up corroboration
C07 Ribofuranose scaffold supports kg-scale CPG synthesis of PCSK9 and AGT-targeting conjugates [src_C02] Nat Biotechnol 2024 ribofuranose GalNAc kg-scale Tier 1 score 9.0 [src_A04] Mol Ther Nucl Acids 2025 ribofuranose-based GalNAc Tier 1 score 9.1 High Two independent Tier 1 sources; kg-scale confirmed explicitly
C08 Branching-point stability under ammonia deprotection (55°C × 16 h) is a documented QC checkpoint with risk of truncated cluster impurities [src_C07] OPR&D 2024 triantennary GalNAc multi-gram synthesis Tier 1 score 8.7 [src_A02] Mol Ther Nucl Acids 2024 Tier 1 High Two Tier 1 sources; synthesis protocols specify deprotection conditions explicitly
C09 Di-valent linear siRNA (MSH3+HTT) achieves ≥2 months CNS silencing at potency equivalent to cocktail of two mono-targeting di-valent siRNAs [src_A06] Nucleic Acids Res 2024 PMID 38187561 Tier 1 score 9.3 — Medium Single high-quality Tier 1 source; requires independent replication
C10 Nuclease P1 and RNase T1 mapping are obligatory (not optional) QC tools for di-valent/branched scaffold constructs [src_A06] Nucleic Acids Res 2024 — scaffold QC requirements described Tier 1 [src_C14] Chem Rev 2024 QC enzymes for RNA degradation analysis Tier 1 score 8.5 High Both Tier 1; mechanistic logic also independently self-evident from scaffold architecture
C11 GT-multi-siRNA (GP73+hTERT) enters Hep3B cells without dedicated carrier and inhibits tumor growth within two weeks [src_A09] Pharmaceuticals 2025 PMC12736085 Tier 2 score 8.3 — Medium Single Tier 2 source; efficacy data from one cell line/one xenograft model; needs replication
C12 Sirnaomics muRNA uses engineered labile (SBS) cleavage sites for endo-lysosomal release into two RNAi triggers [src_A12] Sirnaomics HKEX 2257 OPT 2024 presentation Tier 2 score 7.9 [src_A12] Sirnaomics 2023 interim results HKEX filing Tier 2 Medium Two Tier 2 sources from same company; independent third-party data not yet publicly available; TRL preclinical
C13 muRNA assembly requires ~3 major synthesis steps and 42+ nucleotides vs. 1 step / 29–33 nt for mxRNA [src_A12] Sirnaomics 2023 interim results presentation Tier 2 — Medium Company self-disclosure; single source; no independent verification of step count
C14 ASGPR saturation documented at doses >5 mg/kg for individual GalNAc-siRNA conjugates; cocktail co-dosing may accelerate this [src_E15] PMC5762979 Alnylam ASGPR saturation study Tier 1 [src_E15] PMC5680813 Capacity limits of ASGPR-mediated liver targeting Tier 1 High Two independent Tier 1 sources; saturation threshold explicitly quantified
C15 Cocktail ratio CV must be <5% across batches for regulatory acceptance as a fixed-composition mixture drug product [src_E14] Regulatory expectation derived from ICH Q6A and standard mixture-API precedent — Medium Specific CV value is regulatory standard inference; no single primary source quotes this directly for siRNA cocktail

Source Details

[src_A08]

  • Title: US Patent 9187746B2 — Dual targeting siRNA agents (Alnylam)
  • Year: 2015 (granted); expires 2031
  • URL: https://patents.google.com/patent/US9187746B2/en
  • Tier: 1 | Score: 8.7
  • Key data: Claim 1 — PCSK9+XBP-1 covalently linked via disulfide; each duplex ≤30 nt; linker options: disulfide, HEG, peptide (1–10 aa), RNA/DNA

[src_A02]

  • Title: Application of improved GalNAc conjugation for cost-effective dual-target siRNA (ANGPTL3+Lp(a))
  • Venue: Mol Ther Nucl Acids | Year: 2024
  • URL: https://pubmed.ncbi.nlm.nih.gov/38204163
  • Tier: 1 | Score: 9.0
  • Key data: Pyran-derived TrisGal-6; ANGPTL3 knockdown equivalent to L96; Figure 2 step-count comparison; no competing interests

[src_A04]

[src_A06]

  • Title: A Programmable Dual-Targeting Di-valent siRNA Scaffold (MSH3+HTT, CNS)
  • Venue: Nucleic Acids Res | Year: 2024 | PMID: 38187561
  • URL: https://pubmed.ncbi.nlm.nih.gov/38187561
  • Tier: 1 | Score: 9.3
  • Key data: Linear di-valent siRNA; ≥2 months silencing in mouse CNS; programmable across MSH3/HTT and APOE/JAK1 pairs; equivalent to cocktail mixture; Khvorova lab UMass

[src_A09]

  • Title: Branched Dual Gene-Targeted Multi-siRNA (GP73+hTERT, liver cancer)
  • Venue: Pharmaceuticals | Year: 2025 | PMC: 12736085
  • URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC12736085/
  • Tier: 2 | Score: 8.3
  • Key data: GT-multi-siRNA biosynthesized in E. coli; enters Hep3B without carrier; tumor growth inhibition within 2 weeks; limited dose-response characterization

[src_A10]

  • Title: Diamine-Scaffold GalNAc-siRNA Conjugate (novel scaffold synthesis)
  • Venue: RSC Advances | Year: 2024
  • URL: https://pubs.rsc.org/en/content/articlehtml/2024/ra/d4ra03023k
  • Tier: 1 | Score: 8.6
  • Key data: Diamine core; matches NAG37 delivery efficiency; PS-linkage at ligand-oligomer junction boosts silencing; TTR knockdown data

[src_A12]

[src_C02]

  • Title: Ribofuranose-based GalNAc — kilogram-scale CPG synthesis (PCSK9/AGT)
  • Venue: Nat Biotechnol | Year: 2024
  • URL: https://pubmed.ncbi.nlm.nih.gov/41810141/
  • Tier: 1 | Score: 9.0
  • Key data: kg-scale CPG synthesis demonstrated; PCSK9 and AGT targeting confirmed

[src_C04]

  • Title: Advancement of GalNAc Drugs in ASGPR-Targeted Hepatocyte Delivery
  • Venue: Biomed Pharmacother | Year: 2025
  • URL: https://pubmed.ncbi.nlm.nih.gov/40068307/
  • Tier: 1 | Score: 8.9
  • Key data: Comprehensive review; ASGPR Kd values; GalNAc valency-binding relationship

[src_C07]

  • Title: Practical Synthesis of Triantennary GalNAc (multi-gram scalable)
  • Venue: OPR&D (ACS) | Year: 2024
  • URL: https://pubs.acs.org/doi/10.1021/acs.oprd.5c00122
  • Tier: 1 | Score: 8.7
  • Key data: Convergent synthesis route; deprotection conditions 55°C × 16 h; branching-point stability documented; multi-gram scalability

[src_C14]

  • Title: Technologies for RNA Degradation & Induced RNA Decay (QC enzymes)
  • Venue: Chem Rev | Year: 2024
  • URL: https://pubs.acs.org/doi/10.1021/acs.chemrev.4c00472
  • Tier: 1 | Score: 8.5
  • Key data: Nuclease P1 (broad single-strand 3'-phosphate cleavage), RNase T1 (G-specific), usage in oligonucleotide QC mapping

[src_D03]

  • Title: Bioconjugated Oligonucleotides: phosphoramidite chemistries & suppliers
  • Venue: Semin Cell Dev Biol | Year: 2019
  • URL: https://pubmed.ncbi.nlm.nih.gov/30608140
  • Tier: 1 | Score: 8.1
  • Key data: Standard vs. specialty phosphoramidite availability; 2'-F, 2'-OMe as commodity vs. linker amidites as specialty

[src_D15]

[src_E11] — NEW (appended to sources.jsonl as src_E11)

  • Title: Disulfide-Containing Parenteral Delivery Systems and Their Redox-Biological Fate
  • Venue: J Control Release | Year: 2014 (foundational review, mechanism unchanged)
  • URL: https://www.sciencedirect.com/science/article/abs/pii/S0168365914004118
  • Tier: 1 | Score: 7.2 (−0.6 for age; mechanism stable)
  • Key data: Intracellular GSH 1–10 mM; extracellular plasma GSH ~2–20 µM; ~500-fold gradient drives intracellular disulfide cleavage

[src_E12] — NEW (appended to sources.jsonl as src_E12)

[src_E13] — NEW (appended to sources.jsonl as src_E13)

  • Title: Targeted delivery of oligonucleotides using multivalent protein–carbohydrate interactions
  • Venue: Chemical Society Reviews (RSC) | Year: 2023
  • DOI: 10.1039/D2CS00788F
  • URL: https://pubs.rsc.org/en/content/articlehtml/2023/cs/d2cs00788f
  • Tier: 1 | Score: 8.6
  • Key data: Alnylam trivalent GalNAc Kd = 2.3 nM; triantennary to tetraantennary gain only modest; 10^6-fold affinity increase from mono to triantennary; cluster effect mechanism

[src_E14] — NEW (appended to sources.jsonl as src_E14)

  • Title: ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and Drug Products (Chemical Substances)
  • Venue: ICH / FDA | Year: 1999; still authoritative
  • URL: https://www.ich.org/page/quality-guidelines
  • Tier: 1 | Score: 7.5 (−1 for age; regulatory guidance still in force)
  • Key data: Specifications for complex/mixture APIs; composition ratio control requirements; <5% CV inference from mixture-API precedent (no specific number for siRNA cocktails — flagged)
  • Notes: [Unverified for specific siRNA cocktail CV: the <5% figure reflects regulatory practice inference, not a specific FDA siRNA guidance document. Should be confirmed against FDA OPQ communications on co-formulated nucleic acids]

[src_E15] — NEW (appended to sources.jsonl as src_E15)

  • Title: Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced ASGPR Expression
  • Venue: Mol Ther | Year: 2017 | PMC: 5762979
  • URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC5762979/
  • Tier: 1 | Score: 8.3
  • Key data: Kd ~2 nM for triantennary GalNAc–ASGPR; receptor saturation documented at >5 mg/kg; simulations: Kd = 2 nM, kon = 1 × 10^5 M−1 s−1; ASGPR ~600 nM intrahepatic concentration

Counter-Evidence Section

CE01 — Cocktail routes may not face meaningful ASGPR saturation at clinical doses

The saturation threshold documented in src_E15 (>5 mg/kg) is based on single-molecule dosing. GalNAc-siRNA clinical doses (0.1–0.5 mg/kg for inclisiran; ~1–3 mg/kg for early-stage programs) are below the saturation threshold even with two molecules combined at equal molar ratios. The ASGPR saturation argument for co-formulated cocktails may be overstated for the dose ranges currently explored clinically.

  • Source: PMC5762979 Tier 1; clinical dose data from inclisiran label
  • Handling: Retain in text but qualify with clinical dose context; receptor saturation is a valid concern at high doses, not universally applicable

CE02 — Covalent tandem constructs have not advanced beyond conference-stage data

Alnylam's Bis-RNAi program (src_A08 and conference posters) has not resulted in a clinical IND as of 2026. The patent is held but no IND was filed. This suggests the convergent-synthesis and hetero-duplex purification challenges may be more difficult to resolve than the paradigm description implies, or that the cocktail approach was judged simpler for the PCSK9+ANGPTL3 indication (vutrisiran/siRNA combination approach used instead).

  • Source: Absence of ClinicalTrials.gov registration; confirmed by src_E02 (Arrowhead ARO-DIMER-PA is the first clinical dual-target construct, not Alnylam's disulfide design)
  • Handling: Acknowledge that covalent tandem has not yet reached clinical validation; this is an important caveat for the paradigm's commercial maturity claim

CE03 — muRNA and cocktail regulatory precedent is genuinely undeveloped

No regulatory submission for a multi-siRNA muRNA or a co-formulated siRNA cocktail as a single IND has been publicly reported as of 2026. The CMC framework for defining "the API" as a mixture of two siRNA species, or as a single molecule that generates two species intracellularly, is not yet established by guidance. The <5% CV claim for composition ratio (C15) is inferred from mixture-API precedent, not from FDA nucleic acid-specific guidance.

  • Source: Absence of public FDA guidance on multi-siRNA products; src_A12 muRNA TRL is preclinical
  • Handling: [Unverified: only inference-level support for the regulatory expectation in C15. The chapter text appropriately frames this as "typically" rather than a hard requirement. Recommend adding a qualifying statement in the final chapter]

CE04 — The avidity "plateau" from trivalent to tetravalent is context-dependent

The claim that going from triantennary to tetraantennary provides only modest affinity gain (C05) is based on competition assay data from isolated receptor systems. In intact hepatocytes with ~500,000 ASGPR copies per cell at 15-min recycling, the practical uptake difference between valency-3 and valency-4 constructs may differ from in vitro Kd data depending on cluster geometry and internalization kinetics. For dual-target constructs that are larger and more rigid than single-target constructs, the optimal valency has not been systematically measured.

  • Source: PMC11609720 Tier 2; PMC5762979 Tier 1
  • Handling: The Kd data is valid for the current claim; the caveat is that valency optimization for dual-target constructs is an open experimental question

CE05 — Biosynthetic production of branched siRNA introduces sequence fidelity risks not present in chemical synthesis

GT-multi-siRNA (src_A09) is biosynthesized in E. coli, which means the product is subject to transcriptional errors, modified nucleotide incorporation limits, and RNA degradation during purification that solid-phase synthesis routes avoid. The paper characterizes the product but does not report a sequence error rate or mass-spectrometric sequence confirmation. For therapeutic purposes, this represents an unresolved CMC risk that chemical synthesis routes for branched scaffolds (src_A06) do not share.

  • Source: PMC12736085 Tier 2; general Tier 1 knowledge of biosynthetic RNA quality
  • Handling: Retain biosynthetic route as a valid alternative but add caveat about sequence fidelity documentation requirements in therapeutic development context
Reference in New Issue View Git Blame Copy Permalink